DSCSA - Drug Supply Chain Security Act

What it says

The Drug Supply Chain Security Act requires product identifiers, including serial numbers, on prescription drug packages, interoperable electronic systems to trace product ownership through the distribution chain, and verification obligations for trading partners to confirm product legitimacy and respond to suspect or illegitimate product.

Paraphrased for plain-language clarity. Always verify against the current published regulation text.

What it means in practice

• The enhanced drug distribution security requirements, effective November 2023, moved the industry from lot-level tracing toward unit-level, serialized traceability, requiring package-level product identifiers and electronic, interoperable tracing systems across the full supply chain.
• Trading partners across the entire distribution chain, manufacturers, wholesalers, dispensers, all carry verification and traceability obligations, meaning DSCSA compliance depends on every link in the chain participating correctly, not just the original manufacturer.
• Suspect and illegitimate product identification and response obligations require documented procedures for investigating and, where confirmed, notifying FDA and trading partners about products that fail verification or show signs of counterfeiting or diversion.

What FDA inspectors look for

• Whether serialized product identifiers are correctly applied and verifiable at the package level, consistent with enhanced drug distribution security requirements.
• Whether electronic tracing systems can actually produce required transaction history and ownership information when requested, not just in theory.
• Whether suspect product investigation and response procedures are documented, followed, and genuinely capable of identifying and addressing potential counterfeiting or diversion.

Related regulations